Breaking News, Collaborations & Alliances

Merck Teams With Aduro Biotech on Cancer Drug Trial

Will evaluate the combination of Aduro’s CRS-207 with Merck’s Keytruda

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Aduro Biotech have expaned their clinical collaboration to include an additional Phase 2 clinical trial. The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease progressed following prior treatment. Earlier this year, Aduro entered a Phase 2 clinical collaboration with Merck...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters